Melanoma Vaccines: Differentiation Antigen Peptides (MART-1:27-35, Tyrosinase and Gp-100) as Immune Targets
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Melanoma vaccine (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Therapeutic Use
- 25 Jan 2013 Biomarkers information updated
- 24 Jan 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 21 Nov 2005 New trial record.